R&D channel feed – Endpoints News

R&D channel feed

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

4 months ago

Lexicon plots Phase 3 trial for diabetic pain drug despite mid-stage flop

4 months ago

Praxis says its essential tremor drug failed a Phase 3 readout, but plans to complete study

4 months ago

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

4 months ago

Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial

4 months ago

Startup working on oral antibodies shares early ulcerative colitis data

4 months ago

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

4 months ago

Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapies

4 months ago

Candel's viral therapy shows promising survival in small pancreatic cancer study

4 months ago

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

4 months ago

Alnylam eyes bigger diseases in more tissue types at ‘inflection point’ for siRNA

4 months ago

FDA lifts hold on Entrada's Duchenne drug after two years

4 months ago

Amgen plans further $200M investment in new tech facility in India

4 months ago

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

4 months ago

FDA approves first drug to treat ultra-rare lipid storage disease

4 months ago

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

4 months ago

Roche no longer wants to be where ‘DNA sequencing goes to die’

4 months ago

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

4 months ago

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

4 months ago

Ascletis’ obesity pill looks similar to Roche’s drug, early data suggest

4 months ago

Will CRISPR matter?

4 months ago

Supernus’ stock sinks after placebo effect derails mid-stage depression study

4 months ago

Exclusive: CRISPR delivery startup, based on UC Berkeley and UCSF science, shuts down

4 months ago

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

4 months ago

First page Previous page 12 13 141516 17 18 Next page Last page